Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody

Histopathology

Volumn 61, Issue 1, 2012, Pages 33-46

  Agostinelli, Claudio ^a   Paterson, Jennifer C ^b   Gupta, Rajeev ^c   Righi, Simona ^a   Sandri, Federica ^a   Piccaluga, Pier P ^a   Bacci, Francesco ^a   Sabattini, Elena ^a   Pileri, Stefano A ^a   Marafioti, Teresa ^b,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunohistochemistry; Leukaemia; LMO2; Lymphoma; Rabbit monoclonal antibody; Solid tumour

Indexed keywords

CD34 ANTIGEN; EPITOPE; LIM PROTEIN; LIM PROTEIN 2; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; BLAST CELL; BURKITT LYMPHOMA; CANCER TISSUE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; GERMINAL CENTER; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM TUMOR; HEMATOPOIETIC TISSUE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENIC MARGINAL ZONE LYMPHOMA; STAINING; THYMUS; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LIM DOMAIN PROTEINS; LYMPHOID TISSUE; LYMPHOMA; PROTO-ONCOGENE PROTEINS; RABBITS; TUMOR MARKERS, BIOLOGICAL;

ORYCTOLAGUS CUNICULUS;

EID: 84862868650     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04198.x     Document Type: Article

References (62)

1. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl Acad. Sci. USA 1991; 88; 4367-4371.
2. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat. Rev. Mol. Cell Biol. 2004; 5; 920-931.
3. Wadman IA, Osada H, Grutz GG et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997; 16; 3145-3157.
4. Valge-Archer VE, Osada H, Warren AJ et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc. Natl Acad. Sci. USA 1994; 91; 8617-8621.
5. Osada H, Grutz GG, Axelson H, Forster A, Rabbitts TH. LIM-only protein Lmo2 forms a protein complex with erythroid transcription factor GATA-1. Leukemia 1997; 11(Suppl. 3); 307-312.
6. Osada H, Grutz G, Axelson H, Forster A, Rabbitts TH. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc. Natl Acad. Sci. USA 1995; 92; 9585-9589.
7. Lahlil R, Lecuyer E, Herblot S, Hoang T. SCL assembles a multifactorial complex that determines glycophorin A expression. Mol. Cell. Biol. 2004; 24; 1439-1452.
8. Hansson A, Zetterblad J, van Duren C, Axelson H, Jonsson JI. The Lim-only protein LMO2 acts as a positive regulator of erythroid differentiation. Biochem. Biophys. Res. Commun. 2007; 364; 675-681.
9. Brandt SJ, Koury MJ. Regulation of LMO2 mRNA and protein expression in erythroid differentiation. Haematologica 2009; 94; 447-448.
10. Warren AJ, Colledge WH, Carlton MB et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78; 45-57.
11. Yamada Y, Pannell R, Forster A, Rabbitts TH. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. Oncogene 2002; 21; 1309-1315.
12. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc. Natl Acad. Sci. USA 2000; 97; 320-324.
13. Gratzinger D, Zhao S, West R et al. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am. J. Clin. Pathol. 2009; 131; 264-278.
14. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2004; 350; 913-922.
15. Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008; 118; 3143-3150.
16. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003; 348; 255-256.
17. Van Vlierberghe P, van Grotel M, Beverloo HB et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108; 3520-3529.
18. Van Vlierberghe P, Beverloo HB, Buijs-Gladdines J et al. Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2008; 22; 1434-1437.
19. Royer-Pokora B, Rogers M, Zhu TH et al. The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemias (T-ALL). Oncogene 1995; 10; 1353-1360.
20. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 1995; 11; 853-862.
21. Hammond SM, Crable SC, Anderson KP. Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk. Res. 2005; 29; 89-97.
22. Dik WA, Nadel B, Przybylski GK et al. Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood 2007; 110; 388-392.
23. Secker-Walker LM, Campana D, Hawkins JM, Sampson RE, Coustan-Smith E. Karyotype and T-cell receptor expression in T-lineage acute lymphoblastic leukemia. Gene Chromosome Cancer 1992; 4; 41-45.
24. Dong WF, Xu Y, Hu QL et al. Molecular characterization of a chromosome translocation breakpoint t(11;14)(p13;q11) from the cell line KOPT-K1. Leukemia 1995; 9; 1812-1817.
25. Larson RC, Fisch P, Larson TA et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 1994; 9; 3675-3681.
26. Larson RC, Lavenir I, Larson TA et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 1996; 15; 1021-1027.
27. Fisch P, Boehm T, Lavenir I et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 1992; 7; 2389-2397.
28. McCormack MP, Young LF, Vasudevan S et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010; 327; 879-883.
29. Neale GA, Mao S, Parham DM, Murti KG, Goorha RM. Expression of the proto-oncogene rhombotin-2 is identical to the acute phase response protein metallothionein, suggesting multiple functions. Cell Growth Differ. 1995; 6; 587-596.
30. Neale GA, Rehg JE, Goorha RM. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood 1995; 86; 3060-3071.
31. Natkunam Y, Zhao S, Mason DY et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007; 109; 1636-1642.
32. Copie-Bergman C, Gaulard P, Leroy K et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J. Clin. Oncol. 2009; 27; 5573-5579.
33. Jais JP, Haioun C, Molina TJ et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22; 1917-1924.
34. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 2004; 350; 1828-1837.
35. Natkunam Y, Farinha P, Hsi ED et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J. Clin. Oncol. 2008; 26; 447-454.
36. Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29; 200-207.
37. Appert A, Nam CH, Lobato N et al. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res. 2009; 69; 4784-4790.
38. Nam CH, Lobato MN, Appert A et al. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions. Oncogene 2008; 27; 4962-4968.
39. Marafioti T, Pozzobon M, Hansmann ML et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004; 103; 188-193.
40. Biddolph SC, Gatter K. Lymphocytes: a practical approach. In Rowland-Jones SL, McMichael AJ eds. Immunohistochemistry of lymphoid organs. Oxford, UK: Oxford University Press, 2000; 27-54.
41. Gupta R, Hong D, Iborra F, Sarno S, Enver T. NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 2007; 316; 590-593.
42. Marafioti T, Pozzobon M, Hansmann ML et al. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br. J. Haematol. 2005; 128; 333-342.
43. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J. Clin. Oncol. 2006; 24; 2472-2479.
44. Paterson JC, Ballabio E, Mattsson G et al. Labeling of multiple cell markers and mRNA using automated apparatus. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 371-381.
45. Sabattini E, Bisgaard K, Ascani S et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J. Clin. Pathol. 1998; 51; 506-511.
46. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 1998; 95; 14863-14868.
47. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
48. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
49. Pike-Overzet K, de Ridder D, Weerkamp F et al. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007; 21; 754-763.
50. Ma S, Guan XY, Beh PS et al. The significance of LMO2 expression in the progression of prostate cancer. J. Pathol. 2007; 211; 278-285.
51. Hao QL, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM. A functional comparison of CD34+ CD38- cells in cord blood and bone marrow. Blood 1995; 86; 3745-3753.
52. Sambandam A, Bell JJ, Schwarz BA et al. Progenitor migration to the thymus and T cell lineage commitment. Immunol. Res. 2008; 42; 65-74.
53. Zlotoff DA, Schwarz BA, Bhandoola A. The long road to the thymus: the generation, mobilization, and circulation of T-cell progenitors in mouse and man. Semin. Immunopathol. 2008; 30; 371-382.
54. McCormack MP, Curtis DJ. The thymus under siege: Lmo2 induces precancerous stem cells in a mouse model of T-ALL. Cell Cycle 2010; 9; 2267-2268.
55. Neale GA, Rehg JE, Goorha RM. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia 1997; 11(Suppl 3); 289-290.
56. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008; 118; 3132-3142.
57. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302; 415-419.
58. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol. Cell. Biol. 2003; 23; 9003-9013.
59. Cubedo E, Maurin M, Jiang X, Lossos IS, Wright KL. PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL. FEBS J. 2011; 278; 3065-3075.
60. Younes SF, Beck AH, Lossos IS et al. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am. J. Surg. Pathol. 2010; 34; 1266-1276.
61. Younes SF, Beck AH, Ohgami RS et al. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am. J. Clin. Pathol. 2011; 135; 697-708.
62. Malumbres R, Fresquet V, Roman-Gomez J et al. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Haematologica 2011; 96; 980-986.